Singular Research Maintains Buy, $28 Target on Synovis Life Technologies

Singular Research reiterates its Buy rating and $28 target price on Synovis Life Technologies SYNO as the company posts strong 4Q results following announced acquisition by Baxter. Singular Research says, "SYNO reported Q4:11 sales of $22.1 million, up 22% and $0.4 million above our forecast. EPS grew 83% to $0.24 from $0.13 in Q4:10, significantly above our $0.17 estimate. Higher than expected sales and wider gross and operating margins contributed to this strength. ...We continue to believe shareholders should stay invested in SYNO as we think there is a possibility of a better offer with contingency rights or a higher price. We see limited risk of at least the current deal not being completed." SYNO closed at $27.92 per share on Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsReiterationM&AIntraday UpdateMarketsAnalyst RatingsSingular Research
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!